» Articles » PMID: 38833013

Deciphering the Role of Zinc Homeostasis in the Tumor Microenvironment and Prognosis of Prostate Cancer

Overview
Journal Discov Oncol
Publisher Springer
Specialty Oncology
Date 2024 Jun 4
PMID 38833013
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Dysregulation of zinc homeostasis is widely recognized as a hallmark feature of prostate cancer (PCa) based on the compelling clinical and experimental evidence. Nevertheless, the implications of zinc dyshomeostasis in PCa remains largely unexplored.

Methods: In this research, the zinc homeostasis pattern subtype (ZHPS) was constructed according to the profile of zinc homeostasis genes. The identified subtypes were assessed for their immune functions, mutational landscapes, biological peculiarities and drug susceptibility. Subsequently, we developed the optimal signature, known as the zinc homeostasis-related risk score (ZHRRS), using the approach won out in multifariously machine learning algorithms. Eventually, clinical specimens, Bayesian network inference and single-cell sequencing were used to excavate the underlying mechanisms of MT1A in PCa.

Results: The zinc dyshomeostasis subgroup, ZHPS2, possessed a markedly worse prognosis than ZHPS1. Moreover, ZHPS2 demonstrated a more conspicuous genomic instability and better therapeutic responses to docetaxel and olaparib than ZHPS1. Compared with traditional clinicopathological characteristics and 35 published signatures, ZHRRS displayed a significantly improved accuracy in prognosis prediction. The diagnostic value of MT1A in PCa was substantiated through analysis of clinical samples. Additionally, we inferred and established the regulatory network of MT1A to elucidate its biological mechanisms.

Conclusions: The ZHPS classifier and ZHRRS model hold great potential as clinical applications for improving outcomes of PCa patients.

References
1.
Hoshida Y . Nearest template prediction: a single-sample-based flexible class prediction with confidence assessment. PLoS One. 2010; 5(11):e15543. PMC: 2990751. DOI: 10.1371/journal.pone.0015543. View

2.
Zheng Y, Jiang L, Hu Y, Xiao C, Xu N, Zhou J . Metallothionein 1H (MT1H) functions as a tumor suppressor in hepatocellular carcinoma through regulating Wnt/β-catenin signaling pathway. BMC Cancer. 2017; 17(1):161. PMC: 5330125. DOI: 10.1186/s12885-017-3139-2. View

3.
Mayakonda A, Lin D, Assenov Y, Plass C, Koeffler H . Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018; 28(11):1747-1756. PMC: 6211645. DOI: 10.1101/gr.239244.118. View

4.
Chen Q, Zhang Z, Yang Q, Shan G, Yu X, Kong C . The role of zinc transporter ZIP4 in prostate carcinoma. Urol Oncol. 2011; 30(6):906-11. DOI: 10.1016/j.urolonc.2010.11.010. View

5.
Costello L, Franklin R . The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots. Mol Cancer. 2006; 5:17. PMC: 1481516. DOI: 10.1186/1476-4598-5-17. View